Measles immunity gaps among children and adolescents with HIV in Zambia despite high measles vaccination and antiretroviral therapy coverage.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
medline:
22
11
2023
pubmed:
7
7
2023
entrez:
7
7
2023
Statut:
ppublish
Résumé
The study objective was to identify measles and rubella immunity gaps among people with HIV (PWH) in Zambia despite high measles vaccine coverage and widespread access to antiretroviral therapy. Nationally representative cross-sectional serosurvey using biorepository specimens. Blood specimens collected in the Zambia Population HIV Impact Assessment survey (ZAMPHIA) of 2016 were tested for measles and rubella immunoglobulin G (IgG) antibodies by enzyme immunoassay. Hierarchical generalized additive models were fit to characterize age-specific measles and rubella seroprevalence profiles by HIV infection status. Log-binomial regression was performed to identify factors associated with seronegativity. Of the 25 383 specimens, a subsample of 11 500 were selected and 9852 (85%) were successfully tested. Measles seroprevalence was lower among PWH compared with HIV-uninfected individuals until approximately 30 years of age. Among children younger than the age of 10 years, measles seroprevalence was 47.2% [95% confidence interval (CI): 32.7, 61.7] in PWH and 76.4% (95% CI: 74.9, 78.0) in HIV-uninfected children in same age category. In contrast, rubella seroprevalence was higher among PWH than HIV-uninfected individuals, particularly for children younger than 10 years (68.6% vs. 44.3%, P < 0.001). Having a detectable viral load was associated with being measles seronegative (adjusted prevalence ratio 0.15, 95% CI: 0.06, 0.38). These results from a nationally representative serosurvey demonstrate persistence of measles immunity gaps among PWH younger than 30 years of age. There is need to implement the World Health Organization's recommendation to revaccinate children living with HIV against measles following immune reconstitution with antiretroviral therapy to protect these children and prevent measles outbreaks.
Identifiants
pubmed: 37418463
doi: 10.1097/QAD.0000000000003634
pii: 00002030-202311010-00013
pmc: PMC10664789
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2021-2029Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Lancet Glob Health. 2021 Mar;9(3):e280-e290
pubmed: 33607028
Future Virol. 2011 Jan 1;6(1):59-71
pubmed: 21339832
J Infect Dis. 2011 Jul;204 Suppl 1:S164-78
pubmed: 21666158
Vaccine. 2021 Jun 16;39(27):3544-3559
pubmed: 34045102
Pediatr Infect Dis J. 2017 Mar;36(3):301-306
pubmed: 27879554
AIDS. 2022 Jul 15;36(9):1305-1306
pubmed: 35833681
J Infect Dis. 2013 Dec 1;208(11):1747-55
pubmed: 23911708
EClinicalMedicine. 2018 Jul 02;1:28-42
pubmed: 31193646
Clin Infect Dis. 2007 Dec 1;45(11):1417-24
pubmed: 17990222
Clin Infect Dis. 2019 Aug 16;69(5):836-844
pubmed: 30452621
Pediatr Infect Dis J. 2017 Dec;36(12):1148-1155
pubmed: 28198789
MMWR Morb Mortal Wkly Rep. 2022 Nov 25;71(47):1489-1495
pubmed: 36417303
J Infect Dis. 2007 Aug 1;196(3):347-55
pubmed: 17597448
Sci Rep. 2022 Jun 17;12(1):10217
pubmed: 35715547
Int J Infect Dis. 2022 Jun;119:201-209
pubmed: 35398300
MMWR Morb Mortal Wkly Rep. 2021 Nov 12;70(45):1563-1569
pubmed: 34758014
Am J Epidemiol. 2019 Dec 31;188(12):2240-2251
pubmed: 31210268
Int J Epidemiol. 2008 Apr;37(2):356-67
pubmed: 18234739
Vaccine. 2019 Jan 29;37(5):732-741
pubmed: 30579756
Lancet Infect Dis. 2008 Aug;8(8):477-89
pubmed: 18652994
Lancet. 2022 Apr 2;399(10332):1336-1346
pubmed: 35367004
Lancet Glob Health. 2022 Feb;10(2):e186-e194
pubmed: 34951973